TBHQ

SKU: orb1221022

Description

Tert-butylhydroquinone (tBHQ) is an antioxidant that induces an antioxidant response through the redox-sensitive transcription factor Nrf2.(In Vitro):TBHQ (t-butylhydroquinone; tBHQ; 0-100 μM; 48 hours; H9c2 cells) alone does not affect H9c2 cells viability. Pre-incubation of the H9c2 cells with various concentrations of tBHQ for 24 hours enhances cell viability which is decreased due to exposure to ethanol in a dose-dependent manner. Treatment with tBHQ markedly enhances the viability of H9c2 cardiomyocytes exposed to ethanol.TBHQ (5 μM; 15 min; H9c2 cells) treatment significantly reduces the amount of apoptotic cells exposed to ethanol.TBHQ (5 μM; H9c2 cells) pre-treatment markedly inhibites the ethanol-induced increase in caspase-3 and Bax expression, and enhances Bcl-2 expression.(In Vivo):TBHQ treatment (50 mg/kg; Intraperitoneal injection; three injections at intervals of 8 h that began 1-h post ICH; CD-1 mice) augments the DNA-Binding activity of Nrf2, attenuates oxidative brain damage and acute neurological deficits afterintracerebral hemorrhage (ICH), attenuates microglial activation with concomitant reduction in the release of proinflammatory cytokine interleukin-1β (IL-1β). TBHQ has the efficacy of post-injury administration in attenuating acute neurological injury after ICH.

Key Properties

• CAS Number: 1948-33-0
• MW: 166.22
• Purity: >98% (HPLC)
• Formula: C₁₀H₁₄O₂
• SMILES: CC(C)(C)c1cc(O)ccc1O
• Target: Keap1-Nrf2
• Solubility: DMSO: 30 mg/mL (180.48 mM)

Bioactivity

• In Vivo:
  TBHQ treatment (50 mg/kg; Intraperitoneal injection; three injections at intervals of 8 h that began 1-h post ICH; CD-1 mice) augments the DNA-Binding activity of Nrf2, attenuates oxidative brain damage and acute neurological deficits afterintracerebral hemorrhage (ICH), attenuates microglial activation with concomitant reduction in the release of proinflammatory cytokine interleukin-1β (IL-1β). TBHQ has the efficacy of post-injury administration in attenuating acute neurological injury after ICH. Animal model: Male CD-1 mice (8-10 weeks old). Dosage: 50 mg/kg. Administration: Intraperitoneal injection; three injections at intervals of 8 hours that began 1h post ICH. Result: The treatment augmented the DNA-binding activity of Nrf2, attenuated brain oxidative damage, attenuated the microglial activation and the expression of IL-1β.
  Read more...
• In Vitro:
  TBHQ (t-butylhydroquinone; tBHQ; 0-100 μM; 48 hours; H9c2 cells) alone does not affect H9c2 cells viability. Pre-incubation of the H9c2 cells with various concentrations of tBHQ for 24 hours enhances cell viability which is decreased due to exposure to ethanol in a dose-dependent manner. Treatment with tBHQ markedly enhances the viability of H9c2 cardiomyocytes exposed to ethanol. TBHQ (5 μM; 15 min; H9c2 cells) treatment significantly reduces the amount of apoptotic cells exposed to ethanol. TBHQ (5 μM; H9c2 cells) pre-treatment markedly inhibites the ethanol-induced increase in caspase-3 and Bax expression, and enhances Bcl-2 expression. Cell Viability Assay Cell line: H9c2 cells. Concentration: 0 μM, 0.625 μM, 1.25 μM, 2.5 μM, 5 μM, 10 μM, 20 μM, 50 μM and 100 μM Incubation time: 48 hours. Result: Enhanced the viability of H9c2 cardiomyocytes exposed to ethanol. Apoptosis Analysis Cell line: H9c2 cells. Concentration: 5 μM. Incubation time: Result: Lowered the amount of apoptotic cells exposed to ethanol. Western blot analysis. Cell line: H9c2 cells. Concentration: 5 μM. Incubation time: Result: Inhibited the ethanol-induced increase in caspase-3 and Bax expression, and enhanced Bcl-2 expression.
  Read more...

Storage & Handling

• Storage: Storage temperature: -20°C. Stability: ≥ 2 years
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

tert-Butylhydroquinone

Quick Database Links

Gene Symbol

Keap1-Nrf2